ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
July 31, 2023 09:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ:...
ITM eröffnet weltweit größte Anlage zur Produktion von Lutetium-177 für zielgerichtete Radionuklidtherapien gegen Krebs
June 13, 2023 02:00 ET
|
ITM Isotope Technologies Munich SE
Neue Herstellungsanlage in Neufahrn bei München verzehnfacht ITMs Produktionskapazitäten Feierliche Eröffnung durch Staatsminister Dr. Florian Herrmann, Leiter der Bayerischen Staatskanzlei ...
ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
June 13, 2023 02:00 ET
|
ITM Isotope Technologies Munich SE
New manufacturing plant in Neufahrn near Munich increases ITM's production capacity tenfoldCeremonial opening by Minister of State, Dr. Florian Herrmann, Head of the Bavarian State Chancellery ...
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
June 05, 2023 05:00 ET
|
ITM Isotope Technologies Munich SE
One of the largest private investment rounds in European biotech to-dateNet proceeds will enhance ITM’s radiopharmaceutical pipeline, bolster commercial infrastructure, expand leading...